These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 9112337

  • 21. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.
    Moulin D, Bianchi A, Boyault S, Sebillaud S, Koufany M, Francois M, Netter P, Jouzeau JY, Terlain B.
    Arthritis Rheum; 2005 Mar; 52(3):759-69. PubMed ID: 15751073
    [Abstract] [Full Text] [Related]

  • 22. Gene polymorphisms of TNF-alpha-308 (G/A), IL-10(-1082) (G/A), IL-6(-174) (G/C) and IL-1Ra (VNTR) in Egyptian cases with type 1 diabetes mellitus.
    Settin A, Ismail A, El-Magd MA, El-Baz R, Kazamel A.
    Autoimmunity; 2009 Jan; 42(1):50-5. PubMed ID: 19127455
    [Abstract] [Full Text] [Related]

  • 23. Expression of interleukin-1 beta and interleukin-1 receptor antagonist in oxLDL-treated human aortic smooth muscle cells and in the neointima of cholesterol-fed endothelia-denuded rabbits.
    Lin SJ, Yen HT, Chen YH, Ku HH, Lin FY, Chen YL.
    J Cell Biochem; 2003 Mar 01; 88(4):836-47. PubMed ID: 12577317
    [Abstract] [Full Text] [Related]

  • 24. [The protective effect of interleukin-1 receptor antagonist on postischemic reperfused myocardium and its possible mechanism].
    Li YJ, Ding WH, Gao W, Huo Y, Hong T, Zhu RY, Ma DL.
    Zhonghua Yi Xue Za Zhi; 2004 Apr 02; 84(7):548-53. PubMed ID: 15144587
    [Abstract] [Full Text] [Related]

  • 25. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, Dunstan C, Kollias G, Steiner G, Smolen J, Schett G.
    Arthritis Rheum; 2004 Jan 02; 50(1):277-90. PubMed ID: 14730626
    [Abstract] [Full Text] [Related]

  • 26. Interleukin-1 receptor antagonist intervenes in signaling between different types of synoviocytes in rats with adjuvant arthritis.
    Zheng YQ, Wei W, Dai M, Zhu L, Jia XY, Wang Y.
    Acta Pharmacol Sin; 2006 Jan 02; 27(1):111-8. PubMed ID: 16364217
    [Abstract] [Full Text] [Related]

  • 27. In vitro production of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in insulin-dependent diabetes mellitus.
    Ohno Y, Aoki N, Nishimura A.
    J Clin Endocrinol Metab; 1993 Oct 02; 77(4):1072-7. PubMed ID: 8408455
    [Abstract] [Full Text] [Related]

  • 28. Increased production of intracellular interleukin-1 receptor antagonist type I in the synovium of mice with collagen-induced arthritis: a possible role in the resolution of arthritis.
    Gabay C, Marinova-Mutafchieva L, Williams RO, Gigley JP, Butler DM, Feldmann M, Arend WP.
    Arthritis Rheum; 2001 Feb 02; 44(2):451-62. PubMed ID: 11229477
    [Abstract] [Full Text] [Related]

  • 29. Interleukin (IL)-4 inhibits phorbol-ester induced HIV-1 expression in chronically infected U1 cells independently from the autocrine effect of endogenous tumour necrosis factor-alpha, IL-1beta, and IL-1 receptor antagonist.
    Goletti D, Kinter AL, Coccia EM, Battistini A, Petrosillo N, Ippolito G, Poli G.
    Cytokine; 2002 Jan 07; 17(1):28-35. PubMed ID: 11886168
    [Abstract] [Full Text] [Related]

  • 30. Production of interleukin (IL)-1beta, IL-1 receptor antagonist and IL-10 by blood mononuclear cells in chronic arthritis.
    Andersen LS, Petersen J, Bendtzen K.
    Cytokine; 2000 Jan 07; 12(1):62-8. PubMed ID: 10623444
    [Abstract] [Full Text] [Related]

  • 31. Decreased IL-4 production in new onset type I insulin-dependent diabetes mellitus.
    Berman MA, Sandborg CI, Wang Z, Imfeld KL, Zaldivar F, Dadufalza V, Buckingham BA.
    J Immunol; 1996 Nov 15; 157(10):4690-6. PubMed ID: 8906850
    [Abstract] [Full Text] [Related]

  • 32. Anti-inflammatory effects of hepatocyte growth factor: induction of interleukin-1 receptor antagonist.
    Molnar C, Garcia-Trevijano ER, Ludwiczek O, Talabot D, Kaser A, Mato JM, Fritsche G, Weiss G, Gabay C, Avila MA, Tilg H.
    Eur Cytokine Netw; 2004 Nov 15; 15(4):303-11. PubMed ID: 15627638
    [Abstract] [Full Text] [Related]

  • 33. Interleukin 1 receptor antagonist and tumor necrosis factor-alpha gene polymorphism in patients with end-stage renal failure.
    Shu KH, Cheng CH, Wu MJ, Chen CH, Lee WC.
    Ren Fail; 2005 Nov 15; 27(1):53-7. PubMed ID: 15717635
    [Abstract] [Full Text] [Related]

  • 34. Involvement of TNF alpha, IL-1 beta and IL-1 receptor antagonist in LPS-induced rabbit uveitis.
    Mo JS, Matsukawa A, Ohkawara S, Yoshinaga M.
    Exp Eye Res; 1998 May 15; 66(5):547-57. PubMed ID: 9628802
    [Abstract] [Full Text] [Related]

  • 35. Interleukin-1 beta, interleukin-1 receptor antagonist and interleukin-6 plasma levels and cytokine gene polymorphisms in chronic lymphocytic leukemia: correlation with prognostic parameters.
    Hulkkonen J, Vilpo J, Vilpo L, Koski T, Hurme M.
    Haematologica; 2000 Jun 15; 85(6):600-6. PubMed ID: 10870116
    [Abstract] [Full Text] [Related]

  • 36. Interleukin-1 beta induced transient diabetes mellitus in rats. A model of the initial events in the pathogenesis of insulin-dependent diabetes mellitus?
    Reimers JI.
    Dan Med Bull; 1998 Apr 15; 45(2):157-80. PubMed ID: 9587701
    [Abstract] [Full Text] [Related]

  • 37. Elevated circulating levels of interleukin-1 receptor antagonist but not IL-1 agonists in hemophagocytic lymphohistiocytosis.
    Henter JI, Andersson B, Elinder G, Jakobson A, Lübeck PO, Söder O.
    Med Pediatr Oncol; 1996 Jul 15; 27(1):21-5. PubMed ID: 8614386
    [Abstract] [Full Text] [Related]

  • 38. Monokine antagonism is reduced in patients with IDDM.
    Mandrup-Poulsen T, Pociot F, Mølvig J, Shapiro L, Nilsson P, Emdal T, Røder M, Kjems LL, Dinarello CA, Nerup J.
    Diabetes; 1994 Oct 15; 43(10):1242-7. PubMed ID: 7926295
    [Abstract] [Full Text] [Related]

  • 39. Recombinant IL-1 receptor antagonist protects against TNF-induced lethality in mice.
    Everaerdt B, Brouckaert P, Fiers W.
    J Immunol; 1994 May 15; 152(10):5041-9. PubMed ID: 8176222
    [Abstract] [Full Text] [Related]

  • 40. Circulating interleukin-1 and tumor necrosis factor antagonists in liver disease.
    Tilg H, Vogel W, Wiedermann CJ, Shapiro L, Herold M, Judmaier G, Dinarello CA.
    Hepatology; 1993 Nov 15; 18(5):1132-8. PubMed ID: 8225219
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.